A spiralling health crisis threatens countless children and makes parents’ lives intolerable—and nobody understands what’s causing it. But hope could be round the corner
A Worthing-based biotech company, Allergy Therapeutics, is reportedly closing in on the “holy grail” of allergy research: a vaccine, which uses a genetically engineered plant virus to train the patient’s immune system to damp down its response to allergens over a course of shots.
Allergy Therapeutics plc (LON:AGY) is a market-leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.